Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 Trial.
about
Clinical experience with everolimus in the second-line treatment of advanced renal cell carcinomaIndividualising treatment choices in a crowded treatment algorithmEvaluation of everolimus in renal cell cancer.REACT expanded-access program in patients with metastatic renal cell carcinoma: real-world data from a European subanalysis.Overall survival in renal cell carcinoma after introduction of targeted therapies: a Norwegian population-based study.A gap in disease-specific survival between younger and older adults with de novo metastatic renal cell carcinoma: results of a SEER database analysis.Treatment selection in metastatic renal cell carcinoma: expert consensus.Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases.The clinical potential of temsirolimus in second or later lines of treatment for metastatic renal cell carcinoma.Patient approach in advanced/metastatic renal cell carcinoma: focus on the elderly population and treatment-related toxicity.Advanced kidney cancer: treating the elderly.Targeting PI3K/Akt/mTOR Signaling in Cancer.Future perspectives for mTOR inhibitors in renal cell cancer treatment.Treatment of elderly patients with metastatic renal cell carcinoma.Pharmacotherapy for treating metastatic clear cell renal cell carcinoma.Discontinuation of Everolimus Due to Related and Unrelated Adverse Events in Cancer Patients: A Meta-Analysis.Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study
P2860
Q26783514-15931F66-0293-4A99-BAAE-4FCEC67EBC82Q27023669-426F60E5-A57C-43F5-B780-245F63A1C2E5Q33407015-8CFD5F5F-9163-4152-9576-1C1CEC74D273Q35777625-FE5C6FF9-8417-458E-9F3E-9C4091664815Q37596123-7999D599-AE09-4060-B995-D6A3B7257685Q37602881-5DA58447-433A-41FB-A7B3-739CBB9C46C1Q37999655-85D8185C-94D9-41C2-A015-6F55AD10A2FFQ38105361-A8AA77BC-8D64-46F4-82A3-A572623C7C21Q38136287-44938467-EF8E-472D-ACA3-FE75F75DC249Q38155199-21B59B4F-FDD4-4E0F-B732-848ACB11A259Q38162249-36384FE9-E76E-4DDA-88A0-0C3079EC176BQ38208314-D6AD04D1-F0AC-4FCB-BF85-93B99A1FA7EDQ38372445-E0C3855F-BDF0-4F2F-B509-348AFF196646Q38665322-F7A8ABBE-6E48-4EAA-A952-DF4D297278D5Q39095194-A8AD8F88-B454-43F9-B836-FCAC9A060DBCQ48252794-54FBB0A8-0051-4FBA-81E0-392B39795339Q58796910-D6B54E8D-066B-4D60-B39E-066ECEA76EC3
P2860
Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 Trial.
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Efficacy and safety of everoli ...... atients in the RECORD-1 Trial.
@ast
Efficacy and safety of everoli ...... atients in the RECORD-1 Trial.
@en
Efficacy and safety of everoli ...... atients in the RECORD-1 Trial.
@nl
type
label
Efficacy and safety of everoli ...... atients in the RECORD-1 Trial.
@ast
Efficacy and safety of everoli ...... atients in the RECORD-1 Trial.
@en
Efficacy and safety of everoli ...... atients in the RECORD-1 Trial.
@nl
prefLabel
Efficacy and safety of everoli ...... atients in the RECORD-1 Trial.
@ast
Efficacy and safety of everoli ...... atients in the RECORD-1 Trial.
@en
Efficacy and safety of everoli ...... atients in the RECORD-1 Trial.
@nl
P2093
P2860
P50
P1433
P1476
Efficacy and safety of everoli ...... patients in the RECORD-1 Trial
@en
P2093
Ashok Panneerselvam
Bernard Escudier
Dennis Kim
Emiliano Calvo
Miguel A Climent
Oezlem Anak
Sergio Bracarda
Susanne Osanto
Thomas E Hutson
Ulka Vaishampayan
P2860
P304
P356
10.1016/J.EURURO.2011.12.057
P407
P577
2012-01-05T00:00:00Z